Xenon Pharmaceuticals Inc. (FRA:XP0)
Germany
· Delayed Price · Currency is EUR 38.00
+0.20 (0.53%)
At close: Dec 5, 2025
Xenon Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 104.51 | 142.71 | 148.64 | 57.24 | 175.69 | 45.01 | Upgrade
|
| Short-Term Investments | 357.75 | 484.19 | 489.44 | 534.85 | 376.09 | 131.99 | Upgrade
|
| Cash & Short-Term Investments | 462.27 | 626.91 | 638.08 | 592.09 | 551.77 | 177 | Upgrade
|
| Cash Growth | -29.32% | -1.75% | 7.77% | 7.31% | 211.74% | 25.21% | Upgrade
|
| Accounts Receivable | 0.81 | 1.47 | 0.87 | 0.99 | 2.77 | 1.82 | Upgrade
|
| Receivables | 0.81 | 1.47 | 0.87 | 0.99 | 2.77 | 1.82 | Upgrade
|
| Prepaid Expenses | 17.06 | 6.89 | 6.01 | 7.23 | 4.48 | 2.96 | Upgrade
|
| Total Current Assets | 480.14 | 635.26 | 644.96 | 600.3 | 559.02 | 181.78 | Upgrade
|
| Property, Plant & Equipment | 15.85 | 18.22 | 18.85 | 16.91 | 12.52 | 6.88 | Upgrade
|
| Long-Term Investments | 92.99 | 127.5 | 292.79 | 128.68 | - | - | Upgrade
|
| Long-Term Deferred Tax Assets | 11.75 | 9.67 | 0.8 | 0.51 | 0.47 | 0.52 | Upgrade
|
| Other Long-Term Assets | 7.11 | 7.5 | 7.4 | 7.75 | - | - | Upgrade
|
| Total Assets | 607.84 | 798.14 | 964.8 | 754.15 | 572.01 | 189.19 | Upgrade
|
| Accounts Payable | 4.55 | 5.07 | 8.6 | 8.49 | 3.82 | 3.04 | Upgrade
|
| Accrued Expenses | 32.06 | 23.47 | 17.03 | 13.38 | 9.78 | 7.76 | Upgrade
|
| Current Portion of Leases | 1.5 | 1.37 | 1.3 | 0.49 | 0.61 | 0.27 | Upgrade
|
| Current Income Taxes Payable | 0.23 | 5.69 | 0.35 | - | - | - | Upgrade
|
| Current Unearned Revenue | - | - | - | - | - | 3.64 | Upgrade
|
| Other Current Liabilities | - | - | - | 0.34 | 0.12 | 0.07 | Upgrade
|
| Total Current Liabilities | 38.34 | 35.59 | 27.27 | 22.7 | 14.32 | 14.78 | Upgrade
|
| Long-Term Leases | 6.83 | 7.65 | 9.6 | 9.95 | 7.65 | 3.05 | Upgrade
|
| Other Long-Term Liabilities | 3.16 | - | - | - | - | - | Upgrade
|
| Total Liabilities | 48.33 | 43.24 | 36.88 | 32.65 | 21.97 | 17.83 | Upgrade
|
| Common Stock | 1,475 | 1,457 | 1,436 | 1,065 | 790.9 | 405.48 | Upgrade
|
| Additional Paid-In Capital | 223.78 | 199.15 | 156.76 | 142.11 | 117.5 | 45.36 | Upgrade
|
| Retained Earnings | -1,140 | -899.47 | -665.14 | -482.75 | -357.37 | -278.49 | Upgrade
|
| Comprehensive Income & Other | 0.48 | -1.61 | -0.08 | -3 | -0.99 | -0.99 | Upgrade
|
| Shareholders' Equity | 559.51 | 754.9 | 927.92 | 721.5 | 550.03 | 171.36 | Upgrade
|
| Total Liabilities & Equity | 607.84 | 798.14 | 964.8 | 754.15 | 572.01 | 189.19 | Upgrade
|
| Total Debt | 8.33 | 9.02 | 10.9 | 10.44 | 8.26 | 3.32 | Upgrade
|
| Net Cash (Debt) | 546.93 | 745.39 | 919.97 | 710.33 | 543.52 | 173.68 | Upgrade
|
| Net Cash Growth | -31.08% | -18.98% | 29.51% | 30.69% | 212.94% | 39.05% | Upgrade
|
| Net Cash Per Share | 6.94 | 9.57 | 13.75 | 11.73 | 12.46 | 4.82 | Upgrade
|
| Filing Date Shares Outstanding | 77.28 | 76.54 | 75.43 | 63.04 | 52.94 | 36.83 | Upgrade
|
| Total Common Shares Outstanding | 77.12 | 76.42 | 75.37 | 62.59 | 52.65 | 36.03 | Upgrade
|
| Working Capital | 441.8 | 599.67 | 617.69 | 577.6 | 544.7 | 167 | Upgrade
|
| Book Value Per Share | 7.26 | 9.88 | 12.31 | 11.53 | 10.45 | 4.76 | Upgrade
|
| Tangible Book Value | 559.51 | 754.9 | 927.92 | 721.5 | 550.03 | 171.36 | Upgrade
|
| Tangible Book Value Per Share | 7.26 | 9.88 | 12.31 | 11.53 | 10.45 | 4.76 | Upgrade
|
| Machinery | - | 14.38 | 11.89 | 11 | 10.8 | 12.32 | Upgrade
|
| Leasehold Improvements | - | 9.36 | 9.02 | 4.2 | 7.02 | 6.39 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.